# Pathway Medical Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pathway-medical-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Kirkland, US
- Website: www.pathwaymedical.com
- Total disclosed funding: $147M
- Latest round: Series D (May 20, 2009)
- Investors on record: 9

## About

Pathway Medical Technologies, Inc. delivers advanced medical solutions focused on enhancing patient care through innovative devices and services, primarily for minimally invasive surgeries and diagnostic procedures.Founded in 1998 in Kirkland, US, Pathway Medical Technologies, Inc. specializes in medical devices and services aimed at improving healthcare delivery. In September 2011, the company was acquired by Medrad, a unit of Bayer Healthcare, for an undisclosed amount. The firm has engaged in 7 total funding deals, with its most recent funding round being Series E, raising a total of USD 9.90 mn.Pathway Medical specializes in providing innovative medical solutions designed to address specific health challenges in the healthcare sector. Their core offerings focus on delivering advanced medical devices and services that enhance patient care and streamline clinical workflows. These products are aimed at healthcare providers, including hospitals, specialized clinics, and outpatient facilities, utilized for procedures related to minimally invasive surgeries and diagnostics. The company’s solutions are essential in improving operational efficiency and patient outcomes, serving a diverse clientele across the United States, Canada, and select international locations.Pathway Medical generates revenue through the sale of its medical devices and related services, operating primarily on a B2B model. The company engages directly with healthcare providers, establishing contracts that typically involve bulk purchases of their flagship products. These transactions are structured to accommodate the needs of hospitals and clinics, ensuring timely delivery and support. Pricing plans for these offerings reflect the quality and innovation of the products, with specific terms negotiated during the contract phase, allowing Pathway Medical to maintain strong relationships with its clients while ensuring sustained revenue growth.Although specific details on upcoming products were not disclosed, Pathway Medical is likely to continue its focus on innovation in medical devices. The company may expand into new markets beyond the current presence in the US and Canada, targeting additional international regions within the next few years. The recent acquisition by Medrad could provide additional resources and support for Pathway Medical's expansion efforts and product development, leveraging Bayer Healthcare's broader reach and expertise. The latest funding round in September 2011, which saw a total raise of USD 9.90 mn, could facilitate these growth initiatives.

## Funding rounds

- Series D, May 20, 2009, $43M — Latterell Venture Partners, Oxford Bioscience Partners, Giza Venture Capital, HLM Venture Partners, Forbion, WRF Capital
- Series D, Mar 30, 2009, $40M — Latterell Venture Partners, Oxford Bioscience Partners, Giza Venture Capital, HLM Venture Partners, Forbion
- Series C, Apr 14, 2008, $25M — Latterell Venture Partners, Oxford Bioscience Partners, Giza Venture Capital, HLM Venture Partners, Forbion
- Series B, Nov 1, 2006, $25M — Latterell Venture Partners, Oxford Bioscience Partners, Giza Venture Capital, HLM Venture Partners, Abenex
- Series A, Mar 1, 2005, $15M — Oxford Bioscience Partners, Giza Venture Capital, Orchestra Medical Ventures, Capital A

## Investors

- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series A, Series B, Series C, Series D
- Giza Venture Capital (https://capitalatlas.ai/funds/giza-venture-capital) — Series A, Series B, Series C, Series D
- Orchestra Medical Ventures (https://capitalatlas.ai/funds/orchestra-medical-ventures) — Series A
- Capital A — Series A
- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series B, Series C, Series D
- HLM Venture Partners (https://capitalatlas.ai/funds/hlm-venture-partners) — Series B, Series C, Series D
- Abenex (https://capitalatlas.ai/funds/abenex) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C, Series D
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series D